OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis
Rubeshan Perumal, Neda Bionghi, Camus Nimmo, et al.
European Respiratory Journal (2023) Vol. 62, Iss. 6, pp. 2300639-2300639
Open Access | Times Cited: 13
Rubeshan Perumal, Neda Bionghi, Camus Nimmo, et al.
European Respiratory Journal (2023) Vol. 62, Iss. 6, pp. 2300639-2300639
Open Access | Times Cited: 13
Showing 13 citing articles:
The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience
Kogieleum Naidoo, Rubeshan Perumal, Helen Cox, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. e559-e575
Closed Access | Times Cited: 8
Kogieleum Naidoo, Rubeshan Perumal, Helen Cox, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. e559-e575
Closed Access | Times Cited: 8
Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosis
Prakasini Satapathy, Ramaiah Itumalla, Ahmad Neyazi, et al.
Journal of Biosafety and Biosecurity (2024) Vol. 6, Iss. 1, pp. 13-15
Open Access | Times Cited: 5
Prakasini Satapathy, Ramaiah Itumalla, Ahmad Neyazi, et al.
Journal of Biosafety and Biosecurity (2024) Vol. 6, Iss. 1, pp. 13-15
Open Access | Times Cited: 5
Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia
Gunar Günther, Lusia Mhuulu, Azaria Diergaardt, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 3
Open Access | Times Cited: 5
Gunar Günther, Lusia Mhuulu, Azaria Diergaardt, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 3
Open Access | Times Cited: 5
A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing forMycobacterium tuberculosiscomplex
Claudio U. Köser, Paolo Miotto, Nabila Ismail, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 1, pp. 2400391-2400391
Open Access | Times Cited: 4
Claudio U. Köser, Paolo Miotto, Nabila Ismail, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 1, pp. 2400391-2400391
Open Access | Times Cited: 4
Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis
Ginenus Fekadu, Tadesse Tolossa, Firomsa Bekele, et al.
BMJ Global Health (2025) Vol. 10, Iss. 4, pp. e018220-e018220
Open Access
Ginenus Fekadu, Tadesse Tolossa, Firomsa Bekele, et al.
BMJ Global Health (2025) Vol. 10, Iss. 4, pp. e018220-e018220
Open Access
Identification of novel Mycobacterium tuberculosis leucyl-tRNA synthetase inhibitors with antibacterial activity
Galyna P. Volynets, O. I. Gudzera, С. С. Лукашов, et al.
Future Medicinal Chemistry (2025), pp. 1-9
Closed Access
Galyna P. Volynets, O. I. Gudzera, С. С. Лукашов, et al.
Future Medicinal Chemistry (2025), pp. 1-9
Closed Access
New Triazolopyrimidines with Improved Activity against Mycobacterium tuberculosis
Pogula Sreekanth Reddy, Aditi Deshpande, Eric Greve, et al.
ACS Medicinal Chemistry Letters (2025)
Open Access
Pogula Sreekanth Reddy, Aditi Deshpande, Eric Greve, et al.
ACS Medicinal Chemistry Letters (2025)
Open Access
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance
Christopher Finn McQuaid, Theresa Ryckman, Nicolas A. Menzies, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 8
Open Access | Times Cited: 3
Christopher Finn McQuaid, Theresa Ryckman, Nicolas A. Menzies, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 8
Open Access | Times Cited: 3
Bedaquiline: what might the future hold?
Emily S Shaw, Neil G. Stoker, Jessica Potter, et al.
The Lancet Microbe (2024), pp. 100909-100909
Open Access | Times Cited: 3
Emily S Shaw, Neil G. Stoker, Jessica Potter, et al.
The Lancet Microbe (2024), pp. 100909-100909
Open Access | Times Cited: 3
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
Theresa Ryckman, Christopher Finn McQuaid, Ted Cohen, et al.
The Lancet Global Health (2024) Vol. 12, Iss. 10, pp. e1629-e1637
Open Access | Times Cited: 3
Theresa Ryckman, Christopher Finn McQuaid, Ted Cohen, et al.
The Lancet Global Health (2024) Vol. 12, Iss. 10, pp. e1629-e1637
Open Access | Times Cited: 3
Analysis of Genetic Characteristics Associated with Reduced Bedaquiline Susceptibility in Multidrug-Resistant Mycobacterium tuberculosis
Shanshan Wang, Xiao Xiao, Shulan Dong, et al.
Tuberculosis (2024) Vol. 149, pp. 102572-102572
Closed Access
Shanshan Wang, Xiao Xiao, Shulan Dong, et al.
Tuberculosis (2024) Vol. 149, pp. 102572-102572
Closed Access
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis
Kogieleum Naidoo, Rubeshan Perumal
The Lancet Infectious Diseases (2024)
Closed Access
Kogieleum Naidoo, Rubeshan Perumal
The Lancet Infectious Diseases (2024)
Closed Access
